For patients with type 2 diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with an increased ...

A recent study discovered that individuals using GLP-1 medications may develop severe acid reflux.Researchers discovered that ...

Migraines are one of the world's most common neurological conditions, impacting nearly 15% of people globally. Despite this ...

In older patients with cancer and type 2 diabetes, glucagon-like peptide-1 receptor agonist (GLP-1RA) use was associated with ...

Explore the growing GLP-1 agonists market, driven by rising diabetes and obesity rates. Discover advancements in therapies like Tirzepatide and GZR18, offering both glycemic control and weight loss ...

GLP-1 RAs used by adults with type 2 diabetes and obesity is linked to lower risk for dementia, stroke, and mortality vs ...

PolyPid's proprietary and clinically validated, prolonged-release drug delivery technology aims to subcutaneously deliver GLP ...

A similar study in Gastro Hep Advances found higher odds of GERD and gastroparesis among patients with type 2 diabetes taking GLP-1 agonists versus SGLT-2 inhibitors, but lower odds of acute ...

Longer treatment duration, using semaglutide, higher percentage body fat, and nondiabetic status may be associated with better weight reduction.

A recent phase III randomized trial found an investigational oral small-molecule GLP-1 receptor agonist significantly ...

A clinical trial for semaglutide, the active ingredient in Ozempic, found that it improved blood sugar control in people with ...

Lotte Bjerre Knudsen, Chief Scientific Adviser for Research at Danish pharma giant Novo Nordisk, speaks about GLP-1-based ...